+47.6%
XOP vs MRNA
+511.3%
-463.7%
-18.5%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -0.8% | -2.2% | +1.4% | -0.8% |
| 7D | +2.6% | +5.5% | -2.9% | +2.6% |
| 30D | +15.4% | +158.7% | -143.3% | +15.4% |
| 3M | +12.1% | +182.1% | -170.1% | +11.6% |
| 6M | +19.7% | +151.8% | -132.1% | +20.0% |
| YTD | +52.4% | +393.6% | -341.2% | +46.0% |
| 1Y | +47.6% | +499.5% | -451.9% | +39.3% |
| All | +47.6% | +511.3% | -463.7% | +39.3% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling